Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort : A comparison of Lumipulse and established immunoassays
Abstract INTRODUCTION We assessed the concordance of cerebrospinal fluid (CSF) amyloid beta (Aβ) and tau measured on the fully automated Lumipulse platform with pre‐symptomatic Alzheimer's disease (AD) pathology on amyloid positron emission tomography (PET). METHODS In 72 individuals from the Insight 46 study, CSF Aβ40, Aβ42, total tau (t‐tau), and phosphorylated tau at site 181 (p‐tau181) were measured using Lumipulse, INNOTEST, and Meso Scale Discovery (MSD) assays and inter‐platform Pearson correlations derived. Lumipulse Aβ42 measures were adjusted to incorporate standardization to certified reference materials. Logistic regressions and receiver operating characteristics analysis generated CSF cut‐points optimizing concordance with18 F‐florbetapir amyloid PET status (n = 63). RESULTS Measurements of CSF Aβ, p‐tau181, and their ratios correlated well across platforms (r 0.84 to 0.94, P< .0001); those of t‐tau and t‐tau/Aβ42 correlated moderately (r 0.57 to 0.79, P< .0001). The best concordance with amyloid PET (100% sensitivity and 94% specificity) was afforded by cut‐points of 0.075 for Lumipulse Aβ42/Aβ40, 0.087 for MSD Aβ42/Aβ40 and 17.3 for Lumipulse Aβ42/p‐tau181. DISCUSSION The Lumipulse platform provides comparable sensitivity and specificity to established CSF immunoassays in identifying pre‐symptomatic AD pathology..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring - 13(2021), 1 |
| Beteiligte Personen: |
Keshavan, Ashvini [VerfasserIn] |
|---|
| Anmerkungen: |
© 2021 the Alzheimer's Association |
|---|
| Umfang: |
10 |
|---|
| doi: |
10.1002/dad2.12131 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY004473116 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY004473116 | ||
| 003 | DE-627 | ||
| 005 | 20230307135717.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230214s2021 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/dad2.12131 |2 doi | |
| 028 | 5 | 2 | |a DAD2_DAD212131.xml |
| 035 | |a (DE-627)WLY004473116 | ||
| 035 | |a (WILEY)DAD212131 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Keshavan, Ashvini |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort |b A comparison of Lumipulse and established immunoassays |
| 264 | 1 | |c 2021 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2021 the Alzheimer's Association | ||
| 520 | |a Abstract INTRODUCTION We assessed the concordance of cerebrospinal fluid (CSF) amyloid beta (Aβ) and tau measured on the fully automated Lumipulse platform with pre‐symptomatic Alzheimer's disease (AD) pathology on amyloid positron emission tomography (PET). METHODS In 72 individuals from the Insight 46 study, CSF Aβ40, Aβ42, total tau (t‐tau), and phosphorylated tau at site 181 (p‐tau181) were measured using Lumipulse, INNOTEST, and Meso Scale Discovery (MSD) assays and inter‐platform Pearson correlations derived. Lumipulse Aβ42 measures were adjusted to incorporate standardization to certified reference materials. Logistic regressions and receiver operating characteristics analysis generated CSF cut‐points optimizing concordance with18 F‐florbetapir amyloid PET status (n = 63). RESULTS Measurements of CSF Aβ, p‐tau181, and their ratios correlated well across platforms (r 0.84 to 0.94, P< .0001); those of t‐tau and t‐tau/Aβ42 correlated moderately (r 0.57 to 0.79, P< .0001). The best concordance with amyloid PET (100% sensitivity and 94% specificity) was afforded by cut‐points of 0.075 for Lumipulse Aβ42/Aβ40, 0.087 for MSD Aβ42/Aβ40 and 17.3 for Lumipulse Aβ42/p‐tau181. DISCUSSION The Lumipulse platform provides comparable sensitivity and specificity to established CSF immunoassays in identifying pre‐symptomatic AD pathology. | ||
| 700 | 1 | |a Wellington, Henrietta |4 aut | |
| 700 | 1 | |a Chen, Zhongbo |4 aut | |
| 700 | 1 | |a Khatun, Ayesha |4 aut | |
| 700 | 1 | |a Chapman, Miles |4 aut | |
| 700 | 1 | |a Hart, Melanie |4 aut | |
| 700 | 1 | |a Cash, David M. |4 aut | |
| 700 | 1 | |a Coath, William |4 aut | |
| 700 | 1 | |a Parker, Thomas D. |4 aut | |
| 700 | 1 | |a Buchanan, Sarah M. |4 aut | |
| 700 | 1 | |a Keuss, Sarah E. |4 aut | |
| 700 | 1 | |a Harris, Matthew J. |4 aut | |
| 700 | 1 | |a Murray‐Smith, Heidi |4 aut | |
| 700 | 1 | |a Heslegrave, Amanda |4 aut | |
| 700 | 1 | |a Fox, Nick C. |4 aut | |
| 700 | 1 | |a Zetterberg, Henrik |4 aut | |
| 700 | 1 | |a Schott, Jonathan M |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring |g 13(2021), 1 |w (DE-627)WLY004467973 |x 23528729 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:1 |g extent:10 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2021 |e 1 |g 10 | ||